W
Wuxi Zhikang Hongyi Biotechnology
Innovative oncology solutions with advanced WEE1 inhibitors for late-stage ovarian cancer treatment
About Wuxi Zhikang Hongyi Biotechnology
BioCity Pharma specializes in developing cutting-edge oncology treatments, focusing on late-stage ovarian cancer. The company operates in the biopharmaceutical market, targeting healthcare providers and research institutions. Its business model revolves around the research, development, and commercialization of novel cancer therapies, particularly WEE1 small molecular inhibitors like SC0191. Revenue is generated through clinical trials, partnerships with pharmaceutical companies, and eventual drug sales upon regulatory approval. BioCity Pharma's recent achievement includes obtaining implicit authorization from the National Drug Supervisory Authority (NMPA) for SC0191, which will be used in conjunction with chemotherapy drugs for advanced ovarian cancer. This marks the third clinical permit for the SC0191 project, with the company poised to commence Ib II phase clinical research soon.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2024 | $28M | $110M | Wuxi Innovation Investment Group · Binhu Industrial Group · WuXi Biologics | ↗ |
Growth signals
Latest recorded traffic for Wuxi Zhikang Hongyi Biotechnology is 970 monthly website visits, up 40.6% over the last three months. Wuxi Zhikang Hongyi Biotechnology's team grew 42.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Exclaim RoboticsAutonomous robotic repair for AI data centers. |
Zurich, Switzerland | Operational | 5 | $5M | $20M |
ForgisAI edge software for autonomous industrial machinery |
Schlieren, Switzerland | Operational | |||
Möbius IndustriesUrban mining solutions transforming electronic waste into high-value raw materials using AI and robotics |
Methuen, United States | Operational | |||
Renovo SrlRobotic recycling solutions for end-of-life photovoltaic panels |
Milan, Italy | Operational | |||
HumanoidCommercially scalable AI-powered general-purpose humanoid robots |
London, United Kingdom | Operational | |||
Shenzhen Ruoyu TechnologyEmbodied AI robot brain for multi-platform integration |
Ningbo, China | Operational | |||
RollyyAutonomous Charging Robots for Electric Vehicles |
Espoo, Finland | Operational | |||
Tianjin Jingyi Precision Measurement TechnologyIoT-based pipeline and structure integrity monitoring systems |
China | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Wuxi Zhikang Hongyi Biotechnology in its local ecosystem
The Wuxi Zhikang Hongyi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Wuxi Innovation Investment Group- BGBinhu Industrial Group
WuXi Biologics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Wuxi Zhikang Hongyi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Wuxi Zhikang Hongyi Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









